A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML
for Acute Myeloid Leukemia
44 locations incl. Phoenix
Sponsor: Kura Oncology, Inc.
Sex: All·Age: 18+
Code: NCT05735184·Phase 1·Recruiting·Listed Feb 2023